Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18245008 | 0.78 | SLC22A1 (0.36) | SLC22A1OPRM1SMN1; SMN2OPRD1OPRK1 | |
| SCHEMBL419719 | 0.76 | SLC22A1 (0.36) | SLC22A1OPRM1SMN1; SMN2OPRD1OPRK1 | |
| SCHEMBL18244792 | 0.74 | SLC22A1 (0.34) | SLC22A1OPRM1SMN1; SMN2OPRD1OPRK1 | |
| SCHEMBL1292834 | 0.71 | ATM (0.41) | OPRM1SMN1; SMN2ATMMEN1KMT2A | |
| SCHEMBL14838831 | 0.66 | SLC22A1 (0.40) | SLC22A1OPRM1SMN1; SMN2OPRD1OPRK1 | |
| SCHEMBL26699471 | 0.66 | OPRM1 (0.35) | SLC22A1OPRM1SMN1; SMN2OPRD1OPRK1 | |
| SCHEMBL13755065 | 0.65 | SLC22A1 (0.39) | SLC22A1OPRM1SMN1; SMN2OPRD1OPRK1 | |
| SCHEMBL6994535 | 0.65 | ATM (0.31) | ATMMEN1KMT2APOLB | |
| SCHEMBL11637571 | 0.64 | ALDH1A1 (0.31) | — | |
| SCHEMBL472143 | 0.64 | BRD4 (0.39) | SLC22A1OPRM1SMN1; SMN2OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299260-A1 | Method for Preparing Hexahydro-8-Hydroxy-2, 6-Methano-2H-Chinolizin-3 (4H) -One Esters | CILAG LTD. (CH) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299260-A1 | Method for Preparing Hexahydro-8-Hydroxy-2, 6-Methano-2H-Chinolizin-3 (4H) -One Esters | CYP4Z1, HDHD5, HCAR2 | SLC22A1 2882/4885OPRM1 1042/4885SMN1; SMN2 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.